Search

Your search keyword '"Wu, Weixin"' showing total 266 results

Search Constraints

Start Over You searched for: Author "Wu, Weixin" Remove constraint Author: "Wu, Weixin" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
266 results on '"Wu, Weixin"'

Search Results

1. DPBERT: Efficient Inference for BERT based on Dynamic Planning

2. Genome-wide analysis of the interplay between chromatin-associated RNA and 3D genome organization in human cells.

14. Stress-induced RNA-chromatin interactions promote endothelial dysfunction.

15. Mapping RNA–chromatin interactions by sequencing with iMARGI

19. Locally Adaptive Learning Loss for Semantic Image Segmentation

20. Genome-wide colocalization of RNA–DNA interactions and fusion RNA pairs

21. Multi-dimensional LSTM: A Model of Network Text Classification

26. Traveling wave solutions in a nonlocal dispersal SIR epidemic model with nonlocal time-delay and general nonlinear incidences.

28. Traveling waves for a nonlocal delayed reaction-diffusion SIR epidemic model with demography effects.

29. Synthesis of MPEG-b-PLLA Diblock Copolymers and Their Crystallization Performance with PDLA and PLLA Composite Films.

31. Predicate Invention Based RDF Data Compression

35. PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL

36. PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL

39. Ferroelectric Resistance Switching in Epitaxial BiFeO 3 /La 0.7 Sr 0.3 MnO 3 Heterostructures.

40. Supplementary Table S5 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

41. Data from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

42. Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

44. Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma

45. Data from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma

46. Supplementary Tables S1-S12 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma

47. Supplementary Figures S1-S6 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma

49. The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

Catalog

Books, media, physical & digital resources